Amgen Continues To Feel COVID-19 Sales Impact In Q1
Otezla Stands Out For Coming In $100m Below Consensus
Patients’ COVID-19 anxiety continues to keep them from seeking treatments for psoriasis, migraine and even cancer, Amgen said, blaming the pandemic for much of its 4% decline in first quarter revenue.
